Pharmacotherapy of essential thrombocythemia

Naseema Gangat, Ayalew Tefferi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The natural history of essential thrombocythemia is characterized by an increased incidence of thrombotic and hemorrhagic events and, in the long-term, a tendency for disease transformation to myelofibrosis or acute leukemia. Advanced age and a prior history of thrombosis are the major predictors of thrombotic complications. Objective: The aim of this study was to outline the current evidence and the authors' opinion regarding the clinical management of patients with essential thrombocythemia. Methods: The study reviewed the pertinent literature addressing the management options for essential thrombocythemia patients. Results/conclusions: Cytoreductive agents can reduce the rate of thrombotic events, but do not affect the overall survival or rate of disease transformation. Thus, a risk-adapted strategy is recommended for the management of patients with essential thrombocythemia. High-risk patients with essential thrombocythemia should be treated with cytoreductive therapy and low-dose aspirin. Hydroxycarbamide is the agent of choice in most patients: however, interferon-α is a reasonable alternative in young patients, pregnancy or those intolerant of hydroxycarbamide. Low-risk patients can be safely observed. The management of intermediate-risk patients needs to be individualized: however, low-dose aspirin can be used after excluding acquired von Willebrand's disease. In the future we await the role of molecularly targeted therapy with JAK2 inhibitors in high-risk essential thrombocythemia patients.

Original languageEnglish (US)
Pages (from-to)1679-1685
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume9
Issue number10
DOIs
StatePublished - Jul 2008

Fingerprint

Essential Thrombocythemia
Drug Therapy
Aspirin
von Willebrand Diseases
Primary Myelofibrosis
Risk Management
Interferons
Leukemia
Thrombosis
Survival Rate
Pregnancy

Keywords

  • Aspirin
  • Essential thrombocythemia
  • Hydroxycarbamide
  • Treatment

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacotherapy of essential thrombocythemia. / Gangat, Naseema; Tefferi, Ayalew.

In: Expert Opinion on Pharmacotherapy, Vol. 9, No. 10, 07.2008, p. 1679-1685.

Research output: Contribution to journalArticle

Gangat, Naseema ; Tefferi, Ayalew. / Pharmacotherapy of essential thrombocythemia. In: Expert Opinion on Pharmacotherapy. 2008 ; Vol. 9, No. 10. pp. 1679-1685.
@article{77559a69fac34e2d87085bed3f0ebfb6,
title = "Pharmacotherapy of essential thrombocythemia",
abstract = "Background: The natural history of essential thrombocythemia is characterized by an increased incidence of thrombotic and hemorrhagic events and, in the long-term, a tendency for disease transformation to myelofibrosis or acute leukemia. Advanced age and a prior history of thrombosis are the major predictors of thrombotic complications. Objective: The aim of this study was to outline the current evidence and the authors' opinion regarding the clinical management of patients with essential thrombocythemia. Methods: The study reviewed the pertinent literature addressing the management options for essential thrombocythemia patients. Results/conclusions: Cytoreductive agents can reduce the rate of thrombotic events, but do not affect the overall survival or rate of disease transformation. Thus, a risk-adapted strategy is recommended for the management of patients with essential thrombocythemia. High-risk patients with essential thrombocythemia should be treated with cytoreductive therapy and low-dose aspirin. Hydroxycarbamide is the agent of choice in most patients: however, interferon-α is a reasonable alternative in young patients, pregnancy or those intolerant of hydroxycarbamide. Low-risk patients can be safely observed. The management of intermediate-risk patients needs to be individualized: however, low-dose aspirin can be used after excluding acquired von Willebrand's disease. In the future we await the role of molecularly targeted therapy with JAK2 inhibitors in high-risk essential thrombocythemia patients.",
keywords = "Aspirin, Essential thrombocythemia, Hydroxycarbamide, Treatment",
author = "Naseema Gangat and Ayalew Tefferi",
year = "2008",
month = "7",
doi = "10.1517/14656566.9.10.1679",
language = "English (US)",
volume = "9",
pages = "1679--1685",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Pharmacotherapy of essential thrombocythemia

AU - Gangat, Naseema

AU - Tefferi, Ayalew

PY - 2008/7

Y1 - 2008/7

N2 - Background: The natural history of essential thrombocythemia is characterized by an increased incidence of thrombotic and hemorrhagic events and, in the long-term, a tendency for disease transformation to myelofibrosis or acute leukemia. Advanced age and a prior history of thrombosis are the major predictors of thrombotic complications. Objective: The aim of this study was to outline the current evidence and the authors' opinion regarding the clinical management of patients with essential thrombocythemia. Methods: The study reviewed the pertinent literature addressing the management options for essential thrombocythemia patients. Results/conclusions: Cytoreductive agents can reduce the rate of thrombotic events, but do not affect the overall survival or rate of disease transformation. Thus, a risk-adapted strategy is recommended for the management of patients with essential thrombocythemia. High-risk patients with essential thrombocythemia should be treated with cytoreductive therapy and low-dose aspirin. Hydroxycarbamide is the agent of choice in most patients: however, interferon-α is a reasonable alternative in young patients, pregnancy or those intolerant of hydroxycarbamide. Low-risk patients can be safely observed. The management of intermediate-risk patients needs to be individualized: however, low-dose aspirin can be used after excluding acquired von Willebrand's disease. In the future we await the role of molecularly targeted therapy with JAK2 inhibitors in high-risk essential thrombocythemia patients.

AB - Background: The natural history of essential thrombocythemia is characterized by an increased incidence of thrombotic and hemorrhagic events and, in the long-term, a tendency for disease transformation to myelofibrosis or acute leukemia. Advanced age and a prior history of thrombosis are the major predictors of thrombotic complications. Objective: The aim of this study was to outline the current evidence and the authors' opinion regarding the clinical management of patients with essential thrombocythemia. Methods: The study reviewed the pertinent literature addressing the management options for essential thrombocythemia patients. Results/conclusions: Cytoreductive agents can reduce the rate of thrombotic events, but do not affect the overall survival or rate of disease transformation. Thus, a risk-adapted strategy is recommended for the management of patients with essential thrombocythemia. High-risk patients with essential thrombocythemia should be treated with cytoreductive therapy and low-dose aspirin. Hydroxycarbamide is the agent of choice in most patients: however, interferon-α is a reasonable alternative in young patients, pregnancy or those intolerant of hydroxycarbamide. Low-risk patients can be safely observed. The management of intermediate-risk patients needs to be individualized: however, low-dose aspirin can be used after excluding acquired von Willebrand's disease. In the future we await the role of molecularly targeted therapy with JAK2 inhibitors in high-risk essential thrombocythemia patients.

KW - Aspirin

KW - Essential thrombocythemia

KW - Hydroxycarbamide

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=48049083063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48049083063&partnerID=8YFLogxK

U2 - 10.1517/14656566.9.10.1679

DO - 10.1517/14656566.9.10.1679

M3 - Article

C2 - 18570601

AN - SCOPUS:48049083063

VL - 9

SP - 1679

EP - 1685

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 10

ER -